June 26 (Reuters) - An advisory panel of the U.S.
Centers for Disease Control and Prevention on Thursday
recommended the use of Merck's ( MRK ) respiratory syncytial
virus therapy, Enflonsia, for infants 8 months or younger, whose
mother did not receive a preventive shot during pregnancy.